News summary

Omada Health to present research on weight loss during GLP-1 therapy

Source: Longevity Technology • Published: 21 Oct 2026, 08:41

Summarized by Masters of Longevity from Longevity Technology.

Omada Health’s upcoming presentation outlines a research article comparing a digital GLP-1 support program with usual care, promising insight into program-based weight-management approaches during medication-assisted treatment.

Omada Health to present research on weight loss during GLP-1 therapy
Key Takeaways
  • The study followed 245 adults who started a GLP-1 within the prior eight weeks, comparing program participants to usual care.
  • 151 people enrolled in the digital GLP-1 Care Track while 94 received usual care, per the published analysis.
  • Participants in the GLP-1 Care Track showed greater weight loss and improved body composition versus usual care.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.